Transfer of IND. (a) Merck hereby transfers all right, title and interest in and to the IND to Scynexis as of the Effective Date. (b) Scynexis and Merck shall file the Scynexis FDA Letter and the Merck FDA Letter, respectively, with the FDA within one (1) business day after the Effective Date. Scynexis shall be responsible for the payment of any filing or similar fees payable to the FDA with respect to the transfer of the IND and the Program Compound to the Scynexis.
Appears in 2 contracts
Sources: Termination and License Agreement (Scynexis Inc), Termination and License Agreement (Scynexis Inc)